In the phase 2 MIRO-CKD trial, 12 weeks of balcinrenone combined with dapagliflozin reduced albuminuria compared with dapagliflozin alone added to standard of care in patients with stage 3-4 CKD.
Dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in a randomized trial in China. The study included younger patients who were predominantly ...
Please provide your email address to receive an email when new articles are posted on . Dapagliflozin did not improve diuretic efficiency for patients hospitalized with acute HF. It did, however, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results